Barrier Therapeutics Announces Promising Results From On-Going Phase

Market Wire - In addition, 4 of 13 patients (31%) who were evaluated at three months post-treatment demonstrated both mycological cure stages of clinical development for the treatment of a range of dermatological conditions, including onychomycosis, psoriasis Read More